Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield

Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. I rate PFE stock as Buy.

CryptoAlerta — análise de criptomoedas e mercado em tempo real